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Dilated cardiomyopathy (DCM) is the ﬁnal common
phenotypic pathway for multiple pathological processes that
are characterized by left ventricular (LV) chamber dilation
and systolic dysfunction, and clinically manifested by
congestive heart failure (1). Etiologies may include ante-
cedent viral myocarditis and generalized myopathies,
along with a broad spectrum of sarcomeric, sarcolemmal,
cytoskeletal, or nuclear protein abnormalities. However,
etiology remains idiopathic in approximately two-thirds of
cases (2). Epidemiological studies have estimated the inci-
dence of newly diagnosed DCM to be between 0.57 and
0.73 cases per 100,000 per year among infants and children
<18 years of age (3,4). Despite advances in the medical
management of congestive heart failure, the prognosis
of children with DCM remains poor, with a 5-year
transplantation-free survival of approximately 50% (5).
Nonetheless, normalization of LV size and systolic function
on serial echocardiography has been reported in 25% to 37%
of children (6) and adults (7). The factors associated with
echocardiographic reverse remodeling in idiopathic DCM
have been elusive, often because smaller, single-center series
have been insufﬁciently powered to identify these factors,
but younger age at presentation has been recognized previ-
ously (6).See page 1405In this issue of the Journal, Everitt et al. (8) report the
ﬁndings of the multicenter Pediatric Cardiomyopathy
Registry (PCMR) in 741 children under 18 years of age
who had both LV dilation (LV end-diastolic dimension
[EDD] z-score >2) and LV systolic dysfunction (fractional
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of this paper to disclose.and who had undergone at least 1 follow-up echocardio-
gram 30 days to 2 years after presentation. Patients with
clinical and/or pathological (biopsy or autopsy) evidence of
myocarditis were excluded. The authors found that 22% of
patients surviving to 2 years had normalized LV echocar-
diographic parameters, with a median time to recovery of
9.5 months, whereas 27% continued to have abnormal LV
dimension and function, and 51% had died or undergone
cardiac transplantation. The incidence of normalization of
LV size and function was highest in younger-age children
at their initial presentation; 24% in children <1 year of age
and 26% in children between 1 and 10 years of age.
Conversely, only 10% of children >10 years of age at
presentation demonstrated normalization of LV size and
function on echocardiography. These data are similar to
those from an earlier single-institution study in which 25%
of patients had normalized LV function at a mean follow-
up interval of 4.5 years (6). Patients whose echocardiograms
returned to normal were younger (2.1  1.8 years) at
presentation compared with children with persistently
abnormal LV size and function (4.5  5.9 years). It is
possible that additional patients in the study by Everitt
et al. (8) may have ultimately crossed over into the
normalized group because the cutoff for the follow-up in-
terval was only 2 years, and the curve for the cumulative
incidence rate of recovery continued to increase while the
proportion with persistently abnormal function continued
to decline during the ﬁnal months before study closure.
Indeed, the recent publication by Alexander et al. (9) of the
long-term follow-up of 175 children in the National
Australian Childhood Cardiomyopathy Study reported
normalization of LV function in 33% of all patients and in
69% of survivors 15 years following diagnosis. Nor-
malization in the Australian study was related to greater
baseline LV fractional shortening, but the study population
included children with endomyocardial biopsy–conﬁrmed
myocarditis.
In addition to younger age at presentation, Everitt et al.
(8) identiﬁed less LV dilation, that is, a lower LVEDD
z-score by multivariate analysis, as an additional factor
independently associated with restoration of normal size and
function on echocardiography. For each 1-year decrease in
age, there was a 1.1-fold increase in the likelihood of re-
covery, whereas each 1-unit decrement in LVEDD z-score
resulted in a 1.3-fold increase in recovery of normal LV size
and function. Overall, normalization was achieved in 30% of
children with LVEDD z-scores in the lowest tertile (4.29)
but in only 13% in the highest tertile (6.29). These ob-
servations provide new insight that was previously unavai-
lable because earlier smaller, single-center studies were
inadequately powered to identify the contribution of LV
dimension at diagnosis to the potential for echocardio-
graphic normalization.
These positive observations are tempered, however, by
the ﬁnding that 9 of 96 children who achieved normal LV
size and function within 2 years of diagnosis subsequently
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1415underwent heart transplantation or died. Because their
analysis was limited to a 2-year time frame, the authors
did not report how many of the surviving normalized
patients developed late secondary deterioration in LVEDD
and function. Many questions, therefore, remain unan-
swered and await further investigation. In addition to initial
LVEDD and age at presentation, what factors could help
to identify patients likely to exhibit recovery of normal
LV size and function? Identiﬁcation of novel biomarkers
(10), systematic evaluation of echocardiographic measures
of LV diastolic function and/or systolic strain, and inves-
tigation of genetic variation may aid in prognostication and
in differentiating those children with the potential for
recovery of function from those at high risk for death/
transplantation or persistent LV dysfunction. For example,
the level of N-terminal pro–B-type natriuretic peptide at
3 months after initial diagnosis may be predictive of the
long-term adverse outcome of severe LV dysfunction or
death (11). Moreover, within the “recovered” group, it is
essential to understand the risks and mechanisms for later
secondary decompensation without which withdrawal of
anti–heart failure medications is both premature and
imprudent. How can we differentiate patients with long-
term recovery from those with only short-term, temporary
reverse remodeling? Cardiac magnetic resonance imaging
with late gadolinium enhancement for the identiﬁcation of
focal myocardial ﬁbrosis and inﬂammation or T1 mapping
(12) for the quantiﬁcation of extracellular volume and
diffuse myocardial ﬁbrosis may further inform our under-
standing of the biomechanics of reverse remodeling. Such
studies may also aid in differentiating patients with “per-
manent” recovery of LV function, in whom discontinuation
of medical treatment with anti-heart failure agents is
appropriate, from those who may have achieved only
temporary remission. Finally, new antiﬁbrosis and myo-
cellular therapeutic strategies are needed to increase the
proportion of patients with pediatric DCM who undergo
reverse remodeling and long-term recovery of LV
size and function. The study by Everitt et al. (8) raisesthese provocative questions and opens avenues for further
investigation.
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